Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The protection […]
Source
Pharmaceutical companies with the most orphan drugs Read Post »
Annual Drug Patent Expirations for ABILIFY+ASIMTUFII Abilify Asimtufii is a drug marketed by Otsuka and is included in one NDA. […]
Source
Annual Drug Patent Expirations for XPHOZAH Xphozah is a drug marketed by Ardelyx Inc and is included in one NDA. […]
Source
Annual Drug Patent Expirations for ZOKINVY Zokinvy is a drug marketed by Eiger Biopharms and is included in one NDA. […]
Source
New patent expiration for Eiger Biopharms drug ZOKINVY Read Post »
Annual Drug Patent Expirations for IBSRELA Ibsrela is a drug marketed by Ardelyx Inc and is included in one NDA. […]
Source
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2019 to 2024. Companies […]
Source
Annual Drug Patent Expirations for IGALMI Igalmi is a drug marketed by Bioxcel and is included in one NDA. It […]
Source
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »